| |
| |
 |
| |
|
|
| |
October 31, 2001 |
|
| |
|
|
| |
Launches Corporate Web Site
– Plexxikon, Inc., a privately held structure-based drug discovery company, today announced the addition of two new members to its executive management team. Kathleen Sereda Glaub has been named president and chief financial officer, and Michael V. Milburn, Ph.D., has been named senior vice president and head of research.
"I am pleased to welcome Kathy and Mike to Plexxikon and delighted that they share our vision of building a leadership position in structural biology and chemistry to create a powerful drug discovery platform that can generate a substantial drug pipeline," said Dr. Peter Hirth, chief executive officer of Plexxikon. "Kathy and Mike bring significant talent and experience in their respective fields and are valuable additions to the Plexxikon team as we advance our programs and secure additional financing to support our business."
Ms. Glaub's responsibilities will include corporate development, finance and operations. She has over 18 years experience in corporate development, strategy and financing in the biotechnology and high technology industries. Her experience includes over $4 billion in financing, mergers and acquisitions, and restructuring transactions. Most recently, she served as an independent advisor to private companies for corporate strategy, business development and financing. From 1993 through 1998, Ms. Glaub served as senior vice president and chief financial officer of Cell Genesys, where she was instrumental in the spinout of Abgenix and the acquisition of Somatix Therapy Corporation. Previously, she served as treasurer of Genentech, and also held various treasury and finance management positions at Intel Corporation. Ms. Glaub received a B.A. from the University of California, Berkeley and an M.B.A. from Northwestern University.
Dr. Milburn, who will be responsible for Plexxikon's research programs, brings over 11 years experience in directing structure-based drug discovery to Plexxikon. Most recently, he was vice president of structural biology at Structural GenomiX where he directed the bioinformatics, computational chemistry and crystallography groups. Dr. Milburn also served as department head of structural chemistry at GlaxoSmithKline, where he led the structure-based X-ray crystallography and computational chemistry groups focused on efforts to exploit structural information for drug discovery within the hormone/steroid receptor family and the kinase enzyme family. Dr. Milburn received his Ph.D. in chemistry from the University of California, Berkeley.
Ms. Glaub and Dr. Milburn join an experienced management team at Plexxikon that includes Peter Hirth, Ph.D., co-founder and chief executive officer, and Thomas Kassberg, cofounder and vice president, commercial and business development. Dr. Hirth, a pharmaceutical company executive with over 17 years of industry experience, was formerly the president of SUGEN from its founding through successful acquisition by Pharmacia Corporation in 1999. Mr. Kassberg has 13 years experience in the pharmaceutical industry. He was formerly the head of licensing and business development at SUGEN and prior to that, held a variety of senior financial, sales and strategic planning positions at Bristol-Myers Squibb. In addition to Dr. Hirth and Mr. Kassberg, Plexxikon's founding team includes Joseph Schlessinger, Ph.D., professor and chair of the department of pharmacology at Yale University Medical School, cofounder of SUGEN and chairman of the board of Plexxikon, and Sung-Hou Kim, Ph.D., professor, department of chemistry at the University of California, Berkeley and principal investigator of the Berkeley Structural Genomics Center. Dr. Kim is also the chairman of Plexxikon's scientific advisory board.
Plexxikon, which was founded in December 2000, employs a novel approach to drug discovery in the post-genome era. The company uses innovative structure-based screening, with a focus on families of proteins sharing common folds, or domains, to discover and develop novel chemical scaffolds and small molecule drug leads for pharmaceutically relevant targets. The company plans to develop these drug leads independently and through corporate partnerships.
Plexxikon completed an $8.2 million Series A Preferred Stock round of venture financing on May 11, 2001. Participants in the round included Alta Partners, CW Ventures, Advanced Technology Ventures (ATV), and Kumho Group.
The company also launched its corporate web site, www.plexxikon.com, to communicate comprehensive, up-to-date information about Plexxikon to scientific colleagues, partners, potential employees, investors and the media. For additional information, call 510-647-4000.
2007 | 2006 | 2001 - 2005
Back to Top
|
|
| |
|
|
|
|
| |
| | | | | | |
| | | | | | | | |
| © 2007 Plexxikon Inc. | Site design by |
| |
|
|
